Solifenacin


Concise Prescribing Info
Dosage Details
Oral
Overactive bladder
Adult: 5 mg once daily. If well tolerated, may increase to 10 mg once daily if needed. For patients who are concurrently taking CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): Max dose: 5 mg once daily.
Renal Impairment
CrClDosage
<30Max: 5 mg daily.
Hepatic Impairment
Child-pugh class B: Max: 5 mg daily; Child-pugh class C: Use is not recommended.
Administration
May be taken with or without food. Swallow whole, do not chew/crush.
Contraindications
Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention.
Special Precautions
Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation.
Adverse Reactions
Constipation, dyspepsia, nausea, upper abdominal pain, xerostomia, hypertension, oedema, headache, depression, fatigue, urinary tract infection, blurred vision, cough, influenza.
Overdosage
Acute overdosage may result in severe anticholinergic effects. Chronic overdosage may cause anticholinergic side effects such as blurred vision, tremors and dry skin.
Drug Interactions
May interfere with the prokinetic effects of cisapride and metoclopramide.
Potentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. Strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.
Food Interaction
Concurrent use with St John's wort may increase serum levels of solifenacin.
Action
Description: Solifenacin is a selective M3 antimuscarinic that inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume and decreased detrusor muscle pressure.
Pharmacokinetics:
Absorption: Plasma levels peak 3-8 hr after oral admin. Bioavailability: About 90%.
Distribution: Protein binding: 98%.
Metabolism: Metabolised largely in the liver, mainly by CYP3A4.
Excretion: Terminal half-life: 45-68 hr. Excreted mainly as metabolites in the urine and faeces.
Storage
Store at 25°C.
Disclaimer: This information is independently developed by MIMS based on Solifenacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Solifen
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in